{
    "clinical_study": {
        "@rank": "79133", 
        "brief_summary": {
            "textblock": "To evaluate the safety and immunogenicity of high-titered ALVAC-HIV MN120TMG (vCP205) given\n      sequentially or simultaneously with rgp120/HIV-1SF2 in MF59 adjuvant emulsion in\n      HIV-negative volunteers.\n\n      ALVAC-HIV vCP205 is a second-generation candidate vaccine that can be used to induce a\n      humoral and cellular response against several antigens. vCP205 expresses proteins from two\n      strains of HIV (MN and LAI). rgp120/HIV-1SF2 expresses proteins from a different strain of\n      HIV. This study will help to show how the immune system responds to proteins from more than\n      one strain of virus."
        }, 
        "brief_title": "A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers", 
        "completion_date": {
            "#text": "May 1999", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "ALVAC-HIV vCP205 is a second-generation candidate vaccine that can be used to induce a\n      humoral and cellular response against several antigens. vCP205 expresses proteins from two\n      strains of HIV (MN and LAI). rgp120/HIV-1SF2 expresses proteins from a different strain of\n      HIV. This study will help to show how the immune system responds to proteins from more than\n      one strain of virus.\n\n      Six groups of 25 volunteers each are randomized to receive simultaneous or sequential doses\n      of ALVAC-HIV vCP205 and SF2 rgp120 or control vaccines (ALVAC-RG rabies glycoprotein vCP65\n      or BIOCINE Placebo Vaccine 2). In each group, 21 volunteers receive vaccine and 4 receive\n      control vaccines. Volunteers are stratified by lower or higher risk sexual behavior.\n      Immunizations are given to three groups at months 0, 1, 3, 6, 9, and 12, and to the other\n      three groups at months 0, 1, 6, 9, and 12. Volunteers are followed for 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Volunteers must have:\n\n          -  Normal history and physical exam.\n\n          -  Negative ELISA and Western blot for HIV.\n\n          -  CD4 count >= 400 cells/mm3.\n\n          -  Normal urine dipstick with esterase and nitrite.\n\n        NOTE:\n\n          -  No more than 10 percent of volunteers in each stratum may be over age 50.\n\n        Risk Behavior:\n\n        Allowed for volunteers stratified to the higher risk stratum:\n\n        High risk behavior for HIV infection, such as\n\n          -  injection drug use within the past 12 months.\n\n          -  higher or intermediate risk sexual behavior.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Subjects with the following symptoms or conditions are excluded:\n\n          -  Positive hepatitis B surface antigen.\n\n          -  Medical or psychiatric condition (such as recent suicidal ideation or present\n             psychosis) that precludes compliance.\n\n          -  Occupational responsibilities that preclude compliance.\n\n          -  Active syphilis. NOTE: Subjects with serology documented to be a false positive or\n             due to a remote (> 6 months) treated infection are eligible.\n\n          -  Active tuberculosis. NOTE: Subjects with a positive PPD and a normal chest x-ray\n             showing no evidence of TB and not requiring isoniazid therapy are eligible.\n\n          -  Allergy to egg products or neomycin.\n\n          -  Occupational exposure to birds.\n\n        Subjects with the following prior conditions are excluded:\n\n          -  History of immunodeficiency, chronic illness, autoimmune disease, or use of\n             immunosuppressive medications.\n\n          -  History of anaphylaxis or other serious adverse reactions to vaccines.\n\n          -  Prior immunization against rabies.\n\n          -  History of serious allergic reaction to any substance, requiring hospitalization or\n             emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension).\n\n          -  Prior psychiatric condition (such as history of suicide attempts or past psychosis)\n             that precludes compliance.\n\n          -  History of cancer unless there has been surgical excision that is considered to have\n             achieved cure.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Live attenuated vaccines within 60 days prior to study entry. NOTE: Medically\n             indicated killed or subunit vaccines (e.g., influenza, pneumococcal) do not exclude\n             if administered at least 2 weeks from HIV immunizations.\n\n          -  Experimental agents within 30 days prior to study entry.\n\n          -  Prior HIV vaccines.\n\n          -  Prior rabies immunization.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Blood products or immunoglobulin within the past 6 months.\n\n        For volunteers stratified to the lower risk stratum:\n\n        High risk behavior for HIV infection, such as\n\n          -  injection drug use within the past 12 months.\n\n          -  higher or intermediate risk sexual behavior."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "150", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000847", 
            "org_study_id": "AVEG 022A", 
            "secondary_id": "10573"
        }, 
        "intervention": [
            {
                "intervention_name": "ALVAC-HIV MN120TMG (vCP205)", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "ALVAC-RG Rabies Glycoprotein (vCP65)", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "rgp120/HIV-1 SF-2", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Krestin"
        }, 
        "keyword": [
            "Vaccines, Synthetic", 
            "HIV Envelope Protein gp120", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "Avipoxvirus", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "May 16, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "UAB AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "JHU AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63104"
                    }, 
                    "name": "St. Louis Univ. School of Medicine AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ. of Rochester AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt Univ. Hosp. AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98144"
                    }, 
                    "name": "UW - Seattle AVEG"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers", 
        "overall_official": {
            "last_name": "Corey L", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Corey L, Weinhold K, Montefiori D, McElrath J, Excler JL, Duliege AM, Stablein D. Combination candidate HIV vaccines using a canarypox vector (vCP205) followed by boosting with gp120(SF-2). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:209 (abstract no LB18)"
            }, 
            {
                "citation": "Evans T, Corey L, Clements-Mann ML, Weinhold K, Belshe RB, Excler JL, Duliege AM. CD8+ CTL induced in AIDS vaccine evaluation group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. Int Conf AIDS. 1998;12:277 (abstract no 495/21192)"
            }, 
            {
                "citation": "Corey L, Weinhold K, Montefiori D, Stablein D. CTL and neutralizing antibody responses with a combination HIV-1 vaccine regimen. Int Conf AIDS. 1998;12:636 (abstract no 33221)"
            }, 
            {
                "citation": "Kaslow RA, Rivers C, Goepfert P, Tang J, El Habib R, Weinhold K, Mulligan MJ. Association of HLA class I alleles with cytotoxic T-lymphocyte (CTL) responses to gag and env in recipients of ALVAC-HIV canarypox vaccines. 7th Conference on Retroviruses and Opportunistic Infections. 2000 Jan 30-Feb 2 [Poster 818]"
            }, 
            {
                "PMID": "11170981", 
                "citation": "AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis. 2001 Feb 15;183(4):563-70. Epub 2001 Jan 18."
            }, 
            {
                "PMID": "11873074", 
                "citation": "Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254-61."
            }, 
            {
                "citation": "Bender TJ, Tang J, Rivers C, Mulligan MJ, Kaslow RA. Grouping by HLA class I supertype does not enhance HLA associations with CTL responses to ALVAC-HIV canarypox vaccine components. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 193)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000847"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "JHU AVEG": "39.29 -76.612", 
        "St. Louis Univ. School of Medicine AVEG": "38.627 -90.199", 
        "UAB AVEG": "33.521 -86.802", 
        "UW - Seattle AVEG": "47.606 -122.332", 
        "Univ. of Rochester AVEG": "43.161 -77.611", 
        "Vanderbilt Univ. Hosp. AVEG": "36.166 -86.784"
    }
}